Healio (5/13, Gramigna) reports researchers found in a randomized clinical trial that “patients with opioid dependence who received subcutaneous buprenorphine reported higher satisfaction and lower treatment burden vs. those who took sublingual buprenorphine.” The findings were published in JAMA Network Open.
Psychiatric News (5/13) reports the study’s “results highlight the importance of using patient-reported outcomes when developing medication treatment for substance use disorders.”
Related Links:
— “Patients report subcutaneous buprenorphine preferable to sublingual formulation “Madison Weller, Healio, May 13, 2021